Evidence of measurable or evaluable non-measurable disease per RECIST, v1.1Xx_NEWLINE_xXPatients must have measurable disease based on RECIST 1.1Xx_NEWLINE_xXMeasurable disease by RECIST v1.1Xx_NEWLINE_xXRadiographically measurable or evaluable disease per RECIST v1.1.Xx_NEWLINE_xXPatients must have measurable disease as defined by RECIST v. 1.1 criteria; baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to registrationXx_NEWLINE_xXMeasurable disease (defined by RECIST v. 1.1) or evaluable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease related in the setting of cancer antigen [CA]25 >= 2 x upper limit of normal [ULN])Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1 including at least two cancerous deposits; at least one deposit must be RECIST measurable while at least one deposit must meet criteria for SBRT; non-radiated tumor will be identified prior to randomization on the protocolXx_NEWLINE_xXMeasurable disease by RECIST 1.1 (Phase 2 only)Xx_NEWLINE_xXMeasurable disease as defined by RECIST v1.1Xx_NEWLINE_xXMeasurable or non-measurable disease per RECIST version (v)1.1Xx_NEWLINE_xXSubject in Phase 2 only: must have measurable disease per RECIST 1.1.Xx_NEWLINE_xXHave at least one measurable area of disease based on RECIST 1.1 within the previously radiated fieldXx_NEWLINE_xXMeasurable disease according to RECIST criteria (Version 1.1)Xx_NEWLINE_xXPatient much have measurable disease as defined by RECIST 1.1Xx_NEWLINE_xX4. Measurable disease per RECIST v1.1 and irRECIST;Xx_NEWLINE_xXMeasurable disease as defined by RECIST v1.1Xx_NEWLINE_xXMeasurable disease by RECIST v1.1 with at least one measurable target lesionXx_NEWLINE_xXMeasurable disease per RECIST 1.1.Xx_NEWLINE_xXHas measurable disease assessed by the investigator based on RECIST version 1.1.Xx_NEWLINE_xXHave at least 1 site of disease measurable by RECIST v1.1 that has not been treated with local therapy within 6 months of study treatment. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXMeasurable or non-measurable, but evaluable disease using RECIST v1.1Xx_NEWLINE_xXDose Escalation: Evaluable or measurable disease according to RECIST v1.1 Expansion Cohort (additional 30 patients) Measurable disease according to RECIST v1.1.Xx_NEWLINE_xXMeasurable disease based on RECIST 1.1Xx_NEWLINE_xXMeasurable disease by RECIST v1.1 with at least 1 measurable lesion;Xx_NEWLINE_xXCohort B Safety Run-In (Ribociclib + PDR001 + Fulvestrant): Evaluable or measurable disease by RECIST 1.1Xx_NEWLINE_xXCohort A Dose Expansion (Ribociclib + PDR001): Measurable disease by RECIST 1.1 is requiredXx_NEWLINE_xXExpansion Cohort B (Ribociclib + PDR001 + Fulvestrant): Measurable disease by RECIST 1.1 is requiredXx_NEWLINE_xXHas measurable disease based on RECIST 1.1 as assessed by the central imaging vendor.Xx_NEWLINE_xXMeasureable disease as defined by the RECIST 1.1.Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXPatients must have measurable or evaluable disease per RECIST 1.1 criteriaXx_NEWLINE_xXMeasurable disease per RECIST 1.1.Xx_NEWLINE_xXHave at least one measurable disease based on RECIST 1.1Xx_NEWLINE_xXSubjects must have at least one measurable target lesion according to RECIST version (v)1.1Xx_NEWLINE_xXMeasurable disease, as defined by RECIST v1.1Xx_NEWLINE_xXMeasurable disease by RECIST 1.1Xx_NEWLINE_xXAt least 1 measurable target lesion according to RECIST version 1.1. CNS-only measurable disease as defined by RECIST version 1.1 is allowed.Xx_NEWLINE_xXSubject has at least one measurable lesion per RECIST v1.1.Xx_NEWLINE_xXOne or more measurable or nonmeasurable evaluable lesions per RECIST 1.1.Xx_NEWLINE_xXMeasurable disease as per RECIST v1.1 criteriaXx_NEWLINE_xXMeasurable disease via RECISTXx_NEWLINE_xXPatient must have at least one measurable site of disease as defined by RECIST version (v)1.1, determined by investigator reviewXx_NEWLINE_xXSubject must have measurable neoplastic disease according to the RECIST v1.1;Xx_NEWLINE_xXMeasurable disease according to RECIST Version 1.1Xx_NEWLINE_xXSAFETY RUN-IN: Have either evaluable disease, or have measurable clinical disease: measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by RECIST (version v1.1)Xx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: Have measurable clinical disease: Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by RECIST (version v1.1)Xx_NEWLINE_xXPatients must have measurable or evaluable disease as defined per the RECIST v1.1 except patients with mCRPC.Xx_NEWLINE_xXDocumented disease progression within 6 months prior to study registration, as defined by RECIST criteriaXx_NEWLINE_xXMust have at least 1 site of measurable disease by RECIST criteria, by version 1.1Xx_NEWLINE_xXMeasurable disease by RECIST v1.1Xx_NEWLINE_xXMeasurable disease according to RECIST version (v)1.1 and obtained by imaging within 28 days prior to registration for protocol therapy; NOTE: A subject with prior brain metastasis may be considered if they comply with inclusion criteria belowXx_NEWLINE_xXMeasurable disease as defined by RECISTXx_NEWLINE_xXOne site of measurable disease by RECIST 1.1Xx_NEWLINE_xXPatients with at least one baseline measurable lesion according to RECIST criteria version 1.1.Xx_NEWLINE_xXFor Part G, H, and I: Have measureable disease as defined by RECIST 1.1.Xx_NEWLINE_xXPatients with measurable disease must have at least one target lesion as defined by RECIST 1.1” to be used to assess response on this protocolXx_NEWLINE_xXAt least one measurable lesion as defined by RECIST version (v)1.1 criteria; previously irradiated lesions are not measurable unless the lesion has demonstrated clear progression after radiationXx_NEWLINE_xXParticipants must have measurable disease (RECIST 1.1)Xx_NEWLINE_xXPatients in the dose escalation phase of the study must have measurable or evaluable disease according to RECIST 1.1 criteriaXx_NEWLINE_xXMeasurable disease as defined by RECIST 1.1 is required (Part 2)Xx_NEWLINE_xXSubjects must have measurable lesions (according to standard RECIST 1.1).Xx_NEWLINE_xXPatients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v.1.1.Xx_NEWLINE_xXBaseline measurable disease as measured by RECIST v1. 1.Xx_NEWLINE_xXParticipants must have measurable extracranial disease as defined by RECIST 1.1Xx_NEWLINE_xXMeasurable disease per RECIST version (v)1.1.Xx_NEWLINE_xXHas measurable disease per RECIST 1.1 as assessed by the investigator/radiologyXx_NEWLINE_xXMeasurable disease per RECIST v1.1Xx_NEWLINE_xXOne or more tumors measurable on radiographic imaging as defined by RECIST 1.1.Xx_NEWLINE_xXMeasureable or evaluable disease by RECIST v1.1 for solid tumors prior to the administration of study drugXx_NEWLINE_xXPresence of measurable disease per RECIST v1.1.Xx_NEWLINE_xXPresence of measurable disease as defined by the RECIST version 1.1 Cohort 2: Patient Population: Relapsed/Refractory Soft Tissue Sarcoma or Non-Kit GISTXx_NEWLINE_xXPresence of measurable disease as defined by RECIST version 1.1 Cohort 3: Patient Population: Relapsed/Refractory Triple Negative Breast CancerXx_NEWLINE_xXPresence of measurable disease as defined by RECIST version 1.1 Cohort 4: Patient Population: Relapsed/Refractory Ovarian CancerXx_NEWLINE_xXPresence of measurable disease as defined by RECIST version 1.1Xx_NEWLINE_xXMeasurable disease as per RECIST, version 1.1.Xx_NEWLINE_xXHas measurable disease per RECIST 1.1 as determined by investigatorXx_NEWLINE_xXAt least one radiologically measurable lesion as per RECIST 1.1Xx_NEWLINE_xXPresence of measurable disease per RECIST version (v)1.1; target lesions must not be chosen from a previously irradiated field unless there has been radiographically and/or pathologically documented tumor progression in that lesion prior to enrollment.Xx_NEWLINE_xXPhase 1a: measurable or non-measurable disease per RECIST v 1.1.Xx_NEWLINE_xXMeasurable disease per RECIST version (v)1.1Xx_NEWLINE_xXAt least 1 measurable lesion by RECIST 1.1Xx_NEWLINE_xXMeasurable disease, as defined by RECIST v1.1Xx_NEWLINE_xXPatients must have measurable or evaluable disease per RECIST 1.1 criteriaXx_NEWLINE_xXMeasurable disease, as defined by RECIST v1.1. At least one lesion accessible for biopsyXx_NEWLINE_xXParticipant must have measurable disease outside the field of radiation as defined by RECIST 1.1Xx_NEWLINE_xXPatients must have measurable disease as per RECIST (version 1.1)Xx_NEWLINE_xXPhase II only: Measurable disease according to RECIST v1.1 (Section 8) obtained by imaging within 28 days prior to study registration. Phase Ib: subjects may enroll with or without measurable disease.Xx_NEWLINE_xXMust have measurable disease per RECIST v1.1 Response CriteriaXx_NEWLINE_xXMeasurable or evaluable disease by RECIST v1.1Xx_NEWLINE_xXProgressive disease defined by RECIST criteria =< 14 monthsXx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable disease by RECIST 1.1 is requiredXx_NEWLINE_xXMeasurable disease by RECIST 1.1 criteriaXx_NEWLINE_xXSubject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletionXx_NEWLINE_xXPatients must have measurable disease by RECIST criteria version 1.1Xx_NEWLINE_xXDisease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.Xx_NEWLINE_xXMeasurable disease according to RECIST v1.1 (must be outside central nervous system (CNS))Xx_NEWLINE_xXFor Part 1, cohorts 1-3: evaluable disease (per RECIST version 1.1). For Part 1, cohorts 4-6 and Parts 2 and 3: measurable disease (per RECIST version 1.1)Xx_NEWLINE_xXMeasurable disease per RECIST v1.1Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXPhase II: Patients with advanced/metastatic tumors in the below selected indications, with at least one measurable lesion as determined by RECIST v1.1 or RANOXx_NEWLINE_xXMeasurable disease per RECIST v1.1 by radiographic techniquesXx_NEWLINE_xXHas measurable disease based on RECIST 1.1 as determined by the local site investigator/radiology assessment.Xx_NEWLINE_xXMeasurable disease based on RECIST 1.1.Xx_NEWLINE_xXPart B (all cohorts): Have the presence of measurable disease as defined by the RECIST 1.1.Xx_NEWLINE_xXPresence of at least one measurable lesion according to RECIST v1.1.Xx_NEWLINE_xXTumor measurable by RECIST 1.1 including >= 1 target lesion not planned for biopsyXx_NEWLINE_xXMeasurable tumor lesions according to RECIST 1.1 criteria (Section 10.2).Xx_NEWLINE_xXPresence of at least one measurable lesion according to RECIST v1.1.Xx_NEWLINE_xXEvaluable disease per RECIST 1.1Xx_NEWLINE_xXMeasurable disease by RECIST 1.1 criteriaXx_NEWLINE_xXEvaluable/measurable disease by RECISTXx_NEWLINE_xXRadiographically measurable disease by RECIST v1.1Xx_NEWLINE_xXMeasurable disease by RECIST 1.1Xx_NEWLINE_xXPHASE IB: Measurable disease according to RECIST v1.1Xx_NEWLINE_xXMeasurable disease by physical examination or imaging as defined by RECIST v1.1 criteria or evaluable disease as defined by Gynecologic Cancer Intergroup (GCIG) CA125 criteria.Xx_NEWLINE_xXPresence of at least one measurable lesion as defined by RECIST 1.1Xx_NEWLINE_xXMeasurable disease as per RECIST v1.1 criteriaXx_NEWLINE_xXRadiologically measurable and clinically evaluable disease as per RECIST v1.1Xx_NEWLINE_xXMeasurable disease, according to RECIST, v1.1Xx_NEWLINE_xXHave measurable disease per RECIST version 1.1.Xx_NEWLINE_xXEvaluable or measurable disease as defined by RECIST v1.1 may be enrolled in the dose escalation part; for the dose confirmation part, subjects must have measurable disease by RECIST v1.1 or biomarker for response.Xx_NEWLINE_xXPatients must have measurable disease according to RECIST 1.1Xx_NEWLINE_xXPatient has one or more metastatic tumors measurable per RECIST 1.1 by CT scan ?4 weeks prior to entry into the studyXx_NEWLINE_xXPART II: Patients must have measurable disease, per RECIST 1.1Xx_NEWLINE_xXPatients must have measurable or evaluable advanced and/or metastatic disease by RECIST 1.1.Xx_NEWLINE_xXMeasurable disease as outlined in RECIST 1.1Xx_NEWLINE_xXPatients must have metastatic disease, per RECIST 1.1 for the evaluation of measurable disease.Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1. (in addition to the lesion/s that will be treated with stereotactic radiation therapy)Xx_NEWLINE_xXHave measurable disease, as defined by RECIST version 1.1;Xx_NEWLINE_xXMeasurable disease, defined as per RECIST 1.1 criteriaXx_NEWLINE_xXMeasurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.Xx_NEWLINE_xXMeasurable disease per RECIST 1.1Xx_NEWLINE_xXHave at least one measurable lesions in the liver or at least one measurable lesion in the liver and another measurable lesion elsewhere, based on RECIST version (v.) 1.1Xx_NEWLINE_xXMust have evaluable or measurable disease per RECIST 1.1Xx_NEWLINE_xXMeasurable disease, as defined by RECIST v1.1Xx_NEWLINE_xXMetastatic and/or unresectable (cT4b) urothelial cancer. Measurable disease according to RECIST 1.1 within 30 days prior to registration.Xx_NEWLINE_xXMeasurable disease per RECIST version 1.1.Xx_NEWLINE_xXMeasurable disease by RECIST 1.1Xx_NEWLINE_xXMeasurable disease according to RECIST 1.1.Xx_NEWLINE_xXPresence of measurable disease per RECIST v1.1; target lesions must not be chosen from a previously irradiated field unless there has been radiographically and/or pathologically documented tumor progression in that lesion prior to enrollmentXx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXHave measurable disease per RECIST 1.1 criteria presentXx_NEWLINE_xXHas measurable disease based on RECIST version1.1Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1 as assessed by the investigator. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.Xx_NEWLINE_xXCOHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients must have measurable disease, per RECIST 1.1Xx_NEWLINE_xXCOHORT 2: TRIPLE NEGATIVE BREAST CANCER: Patients must have measurable disease, per RECIST 1.1Xx_NEWLINE_xXCOHORT 3: ENDOMETRIAL CANCER: Patients must have measurable disease, per RECIST 1.1Xx_NEWLINE_xXMeasurable disease as defined by RECIST 1.1Xx_NEWLINE_xXSubjects must have measurable disease according to RECIST (version 1.1)Xx_NEWLINE_xXHistologically-confirmed carcinoma of the breast (either the primary or metastatic lesions) for whom single-agent cytotoxic chemotherapy is indicated. Patients may have either measurable or non-measurable disease according to RECIST version 1.1.Xx_NEWLINE_xXMeasurable disease as defined by RECIST 1.1Xx_NEWLINE_xXHave measurable disease per RECIST version (v)1.1Xx_NEWLINE_xXEvaluable disease by RECIST v1.1.Xx_NEWLINE_xXMeasurable or non-measurable disease, as defined by RECIST 1.1Xx_NEWLINE_xXHave measurable disease as per RECIST version 1.1; at least 1 of the tumor sites must be amenable to biopsy and this may not be the site of disease used to measure antitumor responseXx_NEWLINE_xXPatients receiving PD-1 therapy whose disease is responding or stable (as defined by RECIST v1.1)Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXParticipants must have at least 2 lesions with measurable disease as defined by RECIST Version 1.1Xx_NEWLINE_xXMeasurable disease based on RECIST 1.1.Xx_NEWLINE_xXPresence of measurable disease by RECIST 1.1Xx_NEWLINE_xXParticipants must have measurable disease by RECIST version 1.1Xx_NEWLINE_xXPresence of measurable disease per RECIST v1.1.Xx_NEWLINE_xXMeasurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXMeasurable disease by RECISTXx_NEWLINE_xXMeasurable disease as defined by RECIST v1.1Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXFor disease-specific cohort participants: measurable disease per RECIST v. 1.1Xx_NEWLINE_xXHas at least one measurable lesion per RECIST version 1.1.Xx_NEWLINE_xXMeasurable disease by per RECIST 1.1 criteria; radiographic tumor assessment performed within 28 days of registration.Xx_NEWLINE_xXPhase 1: Participants must have either measurable or evaluable disease as per RECIST 1.1.Xx_NEWLINE_xXPhase 2: Participants must have measurable disease as per RECIST 1.1.Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1 as determined by the investigator/radiology assessment; target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesionsXx_NEWLINE_xXMust have measureable disease as per RECIST Version 1.1 or RANO (for GBM).Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXAll patients enrolled will be required to have measurable disease by RECIST 1.1 criteriaXx_NEWLINE_xXAt least one measurable lesion as defined by RECIST version 1.1; previously irradiated lesions are not measurable unless the lesion has demonstrated clear progression after radiationXx_NEWLINE_xXPatient must have measurable disease based on RECIST 1.1 criteriaXx_NEWLINE_xXHave measurable disease per RECIST v1.1, assessed within 4 weeks prior to study entryXx_NEWLINE_xXMeasurable disease (RECIST 1.1)Xx_NEWLINE_xXMost recent imaging shows measurable disease as defined by RECIST 1.1Xx_NEWLINE_xXMust have measurable disease by radiographic or physical criteria suitable for evaluation according to RECIST v1.1 for documentation of disease response or progression.Xx_NEWLINE_xXPatients must have measurable soft tissue disease per RECIST 1.1Xx_NEWLINE_xXPatients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria version (v)1.1\r\n* NOTE: Scans must be =< 28 days prior to study treatmentXx_NEWLINE_xXMeasurable disease according to RECIST v1.1 within 28 days prior to randomizationXx_NEWLINE_xXSubject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletionXx_NEWLINE_xXMeasurable disease per RECIST 1.1Xx_NEWLINE_xXHave measurable clinical disease: measurable disease, defined as at least 1 measurable lesion on a computed tomography (CT) scan as defined by RECIST (version v1.1)Xx_NEWLINE_xXAt least one index lesion that will not undergo RT or ablation, and which is measurable based on RECIST 1.1Xx_NEWLINE_xXEvaluable or measurable disease based on RECIST 1.1 (50)Xx_NEWLINE_xXPatients must have measurable disease as defined by RECIST v1.1Xx_NEWLINE_xXMeasurable disease (> 10 mm) and have progression of disease based on RECIST criteria; previously irradiated tumor lesions are not considered measurable unless they have progressed since radiationXx_NEWLINE_xXMeasurable disease according to RECIST 1.1 within 28 days prior to registration.Xx_NEWLINE_xXRadiologically measurable disease in the pancreas >= 1 cm, as defined by RECIST v1.1Xx_NEWLINE_xXMeasurable disease by RECIST 1.1 criteriaXx_NEWLINE_xXMeasurable disease by RECIST 1.1Xx_NEWLINE_xXPatients with the presence of at least one measurable lesion as defined by RECIST 1.1 criteria for response assessmentXx_NEWLINE_xXPatients must have measurable disease by RECIST criteriaXx_NEWLINE_xXAt least one measurable lesion based on RECIST version 1.1Xx_NEWLINE_xXFULL STUDY INCLUSION CRITERIA: Patients must have at least 1 measurable lesion according to RECIST version (v) 1.1Xx_NEWLINE_xXMeasurable disease by CT or MRI as per RECIST 1.1. Bone-only disease is not permitted.Xx_NEWLINE_xXMeasurable disease per RECIST v.1.1Xx_NEWLINE_xXDisease status: Subjects must have measurable or evaluable disease, by RECIST v1.1 ± Curie Scale Criteria or RANO/RANO-BMXx_NEWLINE_xXSubject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion.Xx_NEWLINE_xXMeasurable disease according to RECIST 1.1.Xx_NEWLINE_xXMeasurable disease per RECIST 1.1 (primary or metastases)Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXHas measurable disease based on RECIST v1.1 criteriaXx_NEWLINE_xXHave measurable disease per RECIST 1.1 criteria presentXx_NEWLINE_xXMeasurable disease as defined by RECIST criteria (version 1.1)Xx_NEWLINE_xXMeasureable disease according to RECIST Version 1.1Xx_NEWLINE_xXPatients must have measurable disease as defined by RECIST (see Section 6).Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1; target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesionsXx_NEWLINE_xXMeasurable disease, according to modified RECIST 1.1 and irRECISTXx_NEWLINE_xXHave measurable disease per RECIST 1.1 or irRECIST criteria presentXx_NEWLINE_xXAll patients must have measurable disease as defined by RECIST 1.1; patients must also have evidence of disease progression by RECIST 1.1 within 6 months of first dose of study drugXx_NEWLINE_xXPatients must have at least 1 lesion that is measurable using RECIST guidelines\r\n* NOTE: A previously irradiated lesion can be considered a target lesion if the lesion is well defined, measurable per RECIST, and has clearly progressed\r\n* NOTE: For patients with infiltrative disease, evaluable disease needs to be confirmed by pathology if RECIST measurements cannot be madeXx_NEWLINE_xXMeasurable metastatic sites of disease outside of the target lesion undergoing palliative radiation based on RECIST 1.1 as assessed by the investigatorXx_NEWLINE_xXHave measurable or evaluable disease based on RECIST 1.1Xx_NEWLINE_xXMeasurable disease as per the RECIST criteria v 1.1Xx_NEWLINE_xXMeasurable and/or evaluable disease as per the RECIST criteria version (v) 1.1Xx_NEWLINE_xXPatients must have measurable disease according to RECIST 1.1Xx_NEWLINE_xXPatients must have at least one measurable lesion as defined per RECIST 1.1Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXSubjects must have measurable disease as defined by RECIST 1.1Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXHave measurable disease based on RECIST v.1.1Xx_NEWLINE_xXMeasurable disease according to PET Response Criteria, with the exception of patients with cutaneous disease that can be measured and followed by RECIST criteriaXx_NEWLINE_xXPatients may have measurable or non-measurable disease as defined by RECIST 1.1.Xx_NEWLINE_xXAt least 1 measurable lesion (as per RECIST v1.1) progressing or new since last anti-tumor therapy.Xx_NEWLINE_xXMeasurable target tumors using standard imaging techniques (RECIST version [v.] 1.1 criteria)Xx_NEWLINE_xXCERITINIB INCLUSION CRITERIA: Measurable disease by RECIST v1.1Xx_NEWLINE_xXREGORAFENIB INCLUSION CRITERIA: Measurable disease by RECIST v1.1Xx_NEWLINE_xXENTRECTINIB INCLUSION CRITERIA: Measurable disease by RECIST v1.1Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1.Xx_NEWLINE_xXMeasurable or evaluable disease by RECIST v1.1 (not required for the cPoP study)Xx_NEWLINE_xXAt least one measurable lesion as defined by RECIST 1.1Xx_NEWLINE_xXAt least one site of measurable disease on x-ray/CT/MRI scan as defined by RECIST 1.1Xx_NEWLINE_xXRadiographically measurable or evaluable disease per RECIST v1.1.Xx_NEWLINE_xXAt least one measureable lesion as defined by RECIST version 1.1 that has not been previously irradiatedXx_NEWLINE_xXMeasurable disease as defined by RECIST v1.1 criteria. Baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to Enrollment.Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1 and immune related response (irRC) criteriaXx_NEWLINE_xXPHASE II: Patients must have measurable disease based on RECIST 1.1 criteriaXx_NEWLINE_xXMeasurable disease by RECIST 1.1Xx_NEWLINE_xXMeasurable disease as defined by RECIST 1.1 Criteria.Xx_NEWLINE_xXHave evaluable disease by RECIST 1.1 and PCWG2 criteriaXx_NEWLINE_xXCA-125 only disease without RECIST 1.1 measurable or otherwise evaluable diseaseXx_NEWLINE_xXPatients must have disease that is measurable by RECIST version 1.1Xx_NEWLINE_xXPresence of at least one measurable lesion according to RECIST v.1.1Xx_NEWLINE_xXMeasurable disease by RECIST or evaluable disease (e.g., bone metastasis, or lesions which do not fulfill RECIST criteria for metastatic disease)Xx_NEWLINE_xXRadiographically measurable disease per RECIST 1.1Xx_NEWLINE_xXMeasurable tumor lesions according to RECIST 1.1 criteria.[22]Xx_NEWLINE_xXPatients may have measurable or non-measurable disease as defined by RECIST 1.1.Xx_NEWLINE_xXPatient must have measurable disease as per RECIST version 1.1; at least 1 of the tumor sites must be amenable to biopsy and this may not be the site of disease used to measure antitumor responseXx_NEWLINE_xXDisease must be measurable by RECIST 1.1Xx_NEWLINE_xXMeasurable or nonmeasurable disease by RECIST criteria (at least one target or nontarget lesion)Xx_NEWLINE_xXPatients must have measurable disease as per RECIST v1.1Xx_NEWLINE_xXRadiographically measurable per RECIST v1.1.Xx_NEWLINE_xXAt least one measurable lesion of the disease on imaging (CT or MRI; RECIST 1.1)Xx_NEWLINE_xXPhase II cohorts only: patients must have measurable disease according to RECIST v.1.1 criteria. Patients enrolled in Ph Ib cohorts must have evaluable diseaseXx_NEWLINE_xXSubject has measurable disease according to RECIST v1.1 and has relapsed or is refractory to prior therapy.Xx_NEWLINE_xXHas evaluable or measurable disease by RECIST v1.1 criteriaXx_NEWLINE_xXMeasurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.Xx_NEWLINE_xXAt least one measurable/evaluable lesion by RECIST v1.1Xx_NEWLINE_xXMeasurable or evaluable disease per RECIST v1.1Xx_NEWLINE_xXPatient has evaluable disease by RECIST v1.1 (Appendix 3).Xx_NEWLINE_xXMeasurable disease as defined by RECIST version 1.1 by radiologic methods on or after the most recent line of therapy. For Cohort 2, imaging must be available for central review.Xx_NEWLINE_xXExistence of measurable or evaluable disease (as per RECIST 1.1 criteria).Xx_NEWLINE_xXMeasurable disease by CT or MRI, as defined by RECIST v1.1Xx_NEWLINE_xXCurrent progressive disease, as defined by RECIST v1.1Xx_NEWLINE_xXMeasurable or evaluable disease according to RECIST v1.1.Xx_NEWLINE_xXHas ?1 measurable lesion as defined by RECIST 1.1 on imaging studies.Xx_NEWLINE_xXAt least one measurable lesion as defined by RECIST 1.1Xx_NEWLINE_xXSubject has at least one measurable lesion according to RECIST 1.1.Xx_NEWLINE_xXExcluding the lesion intended to undergo radiation, subjects must have at least 1 unresectable, non-bony lesion that is measurable radio-graphically (based on RECIST 1.1).Xx_NEWLINE_xXPart 2 only: have measureable disease by RECISTXx_NEWLINE_xXMeasurable disease as defined by RECIST v1.1 or disease-specific criteria for prostate cancer and malignant pleural mesotheliomaXx_NEWLINE_xXPatients must have at least one measurable or non-measurable lesion (dose escalation only) as defined by RECIST v1.1Xx_NEWLINE_xXIn Stage 1, evaluable disease per RECIST 1.1. In Stage 2, measurable disease.Xx_NEWLINE_xXAt least one radiologically measurable target lesion per RECIST version 1.1Xx_NEWLINE_xXMeasurable tumor lesions according to RECIST 1.1 criteria.Xx_NEWLINE_xXPatients must have at least one measurable lesion per RECIST 1.1 criteria.Xx_NEWLINE_xXPatient with measurable disease according to RECISTXx_NEWLINE_xXMeasurable disease (revised RECIST; Version 1.1)Xx_NEWLINE_xXMeasurable disease (revised RECIST; Version 1.1)Xx_NEWLINE_xXAt least 1 unirradiated target lesion measurable by RECISTXx_NEWLINE_xXPatients must have measurable disease by the Modified RECIST criteriaXx_NEWLINE_xXpatients with NSCLC, UC, mBC, or SCCHN must have measurable disease by RECIST v1.1 criteria with at least one uni-dimensional measurable lesion;Xx_NEWLINE_xXPatients must have measurable disease based on RECIST 1.1, as determined by the site, to be eligibleXx_NEWLINE_xXHas measurable disease per RECIST 1.1 as assessed by the local site investigator/radiologyXx_NEWLINE_xXMeasurable disease per RECIST 1.1 as assessed by the local site investigator/radiology.Xx_NEWLINE_xXFor Part 2, measurable disease as defined by RECIST, Version 1.1 including bone-only diseaseXx_NEWLINE_xXMeasurable Disease by RECIST v1.1Xx_NEWLINE_xXMeasurable disease defined by RECIST criteriaXx_NEWLINE_xXMeasurable disease according to RECIST v1.1.Xx_NEWLINE_xXMeasurable disease per RECIST v1.1 for patients with solid malignancies.Xx_NEWLINE_xXMeasurable disease, according to RECIST v1.1. Note that lesions intended to be biopsied should not be target lesionsXx_NEWLINE_xXPatients must have measurable disease as defined by RECIST 1.1 criteriaXx_NEWLINE_xXFor dose-escalation cohort, patient has at least 1 measurable disease as defined by RECIST criteria (Version 1.1). For dose-expansion cohort, patient has at least 1 measurable disease as defined by RECIST criteria (version 1.1) with a lesion larger than 1.5 cm that can be biopsied by core needle biopsy.Xx_NEWLINE_xXPatients must have measurable disease in at least 2 non-radiated sites as defined by RECIST v1.1; all sites must be evaluated within 4 weeks prior to beginning therapyXx_NEWLINE_xXMust have baseline measurable or evaluable disease per RECISTXx_NEWLINE_xXHave measurable and/or evaluable disease by RECIST 1.1Xx_NEWLINE_xXMeasurable disease by RECIST 1.1 guidelinesXx_NEWLINE_xXPatient has either measurable disease per RECIST v1.1 or at least one predominantly lytic bone lesion must be presentXx_NEWLINE_xXFor the expansion cohort only: measurable disease by RECIST v1.1 with at least one measurable target lesionXx_NEWLINE_xXAbsence of RECIST, v. 1.1 defined measurable disease.Xx_NEWLINE_xXMeasurable disease as assessed by modified RECIST for MPM for thoracic disease (Appendix A) and RECIST 1.1 for extra-thoracic disease (Appendix B).Xx_NEWLINE_xXMeasurable disease as per RECIST 1.1 criteria.Xx_NEWLINE_xXPatients must have measurable disease per RECIST 1.1 criteria; all sites of disease must be evaluated within 4 weeks prior to randomizationXx_NEWLINE_xXMeasurable and/or non-measureable disease by RECIST criteria must be presentXx_NEWLINE_xXMeasurable disease according to RECIST 1.1 within 30 days prior to registration.Xx_NEWLINE_xXPhase III study: evaluable disease - defined as RECIST 1.1 measurable disease OR non-measurable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related in the setting of a cancer antigen [CA]125 >= 2 x upper limit of normal [ULN])Xx_NEWLINE_xXPatients must have measurable disease based on RECIST 1.1Xx_NEWLINE_xXParticipants must have measurable disease by RECIST 1.1Xx_NEWLINE_xXParticipants must have at least a single (RECIST v1.1-defined) measurable lesion.Xx_NEWLINE_xXTriple negative breast cancer patients: participants may have either measurable disease via RECIST 1.1 criteria or evaluable diseaseXx_NEWLINE_xXMeasurable disease according to RECIST Version 1.1Xx_NEWLINE_xXAt least one measurable site of disease in the liver according to RECIST version 1.1 and mRECIST criteriaXx_NEWLINE_xXPatients must measurable disease, as defined by RECIST 1.1 criteriaXx_NEWLINE_xXPresence of measurable disease according to RECIST 1.1Xx_NEWLINE_xXPatients must have measurable disease according to RECIST 1.1Xx_NEWLINE_xXPHASE II: Patients must have measurable disease outside of the primary tumor (pancreas) by RECIST 1.1 criteria; baseline measurements and evaluations of all sites of disease must be obtained =< 4 weeks prior to randomizationXx_NEWLINE_xXCOHORT EXPANSION PHASE: Patient must have measurable lesions as defined by RECIST version 1.1 criteriaXx_NEWLINE_xXMeasurable disease per RECIST 1.1 criteriaXx_NEWLINE_xXSubjects must have measurable disease as defined by RECIST 1.1Xx_NEWLINE_xXPHASE II: Patients must have measurable disease based on RECIST 1.1; baseline measurements and evaluations of all sites of disease must be obtained =< 4 weeks prior to registrationXx_NEWLINE_xXMeasureable disease according to RECIST Version 1.1Xx_NEWLINE_xXPatients must have measurable or non-measurable disease by both RECIST and modified RECIST criteria for pleural tumors as documented by computed tomography (CT) scan; examinations for assessment of measurable disease must have been completed within 28 days prior to registration; examinations for assessment of non-measurable disease must have been performed within 42 days prior to registration; all disease must be assessed and documented on the RECIST 1.1 and Modified RECIST Baseline Tumor Assessment FormXx_NEWLINE_xXPatients must have at least one lesion that meets the definition of measurable disease by RECIST 1.1Xx_NEWLINE_xXMeasurable disease according to RECIST v1.1Xx_NEWLINE_xXMeasurable disease as per RECIST 1.1. Subject must have extracranial metastasis as measurable diseaseXx_NEWLINE_xXMeasurable disease as defined by RECIST 1.1Xx_NEWLINE_xXRadiographically documented measurable disease at study entry (as defined by the RECIST v1.1 criteria).Xx_NEWLINE_xXPresence of measurable disease by RECIST v1.1 for solid tumors or Cheson criteria for B cell NHL (including DLBCL) or HL. For subjects with glioblastoma, presence of measurable disease is not required.Xx_NEWLINE_xXMeasurable disease as defined by RECIST version 1.1Xx_NEWLINE_xXMeasurable disease based on RECIST v1.1.Xx_NEWLINE_xXHas measurable disease based on RECIST 1.1 as determined by the local site investigator/radiology assessment.Xx_NEWLINE_xXMeasurable lesions by RECIST v1.1Xx_NEWLINE_xXPatients must have measurable disease according to RECIST (v.1.1).Xx_NEWLINE_xXFor the dose-escalation phase, measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 (v1.1) is permitted; for the dose expansion phase, patients must have measurable disease by RECIST v1.1Xx_NEWLINE_xXMeasurable disease, as defined by RECIST Version 1.1 (v1.1).Xx_NEWLINE_xXMeasurable disease by investigator assessment with at least 1 unidimensional measurable lesion by RECIST v.1.1 that has not previously been irradiatedXx_NEWLINE_xXPatient has either measurable disease per RECIST 1.1 criteria OR at least one predominantly lytic bone lesion must be presentXx_NEWLINE_xXRadiologically measurable disease according to RECIST v1.1Xx_NEWLINE_xXMeasurable disease per RECIST v1.1Xx_NEWLINE_xXAt least one target lesion that is measurable by RECIST 1.1 for solid tumors, or IWG 2014 for lymphomaXx_NEWLINE_xXAt least one site of disease that is measurable by RECIST (version 1.1) criteria that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiationXx_NEWLINE_xXPhase I (Cohorts A through S) and Phase II: Evaluable or measurable disease per RECIST version 1.1Xx_NEWLINE_xXPhase I (Cohort X): Participants with PIK3CA-mutant tumors and measurable disease per RECIST v1.1Xx_NEWLINE_xXOne or more tumors measurable on CT scan per RECIST 1.1.Xx_NEWLINE_xXMeasurable disease (at least one target lesion) according to RECIST v1.1Xx_NEWLINE_xXMeasurable Disease per RECIST 1.1 as determined by the InvestigatorXx_NEWLINE_xXPresence of measurable disease based on RECIST v1.1.Xx_NEWLINE_xXMeasurable disease on CT or MRI by RECIST 1.1.Xx_NEWLINE_xXMeasurable disease by RECISTXx_NEWLINE_xXAt least one extra-renal measurable target lesion meeting the criteria of RECIST version 1.1Xx_NEWLINE_xXHas measurable disease per RECIST 1.1 as assessed by BICR.Xx_NEWLINE_xXHas measureable or nonmeasurable disease as defined by RECIST 1.1 criteria.Xx_NEWLINE_xXMeasurable disease according to RECIST v1.1Xx_NEWLINE_xXMeasurable disease according to RECIST version 1.1.Xx_NEWLINE_xXSubjects must have measureable disease according to RECIST (version 1.1).Xx_NEWLINE_xXMeasurable/assessable disease, as defined by RECIST v1.1.Xx_NEWLINE_xXParticipants must have measurable disease that is evaluable as per RECIST v1.1Xx_NEWLINE_xXHas measurable disease per RECIST 1.1 as assessed by the investigator/site radiologist.Xx_NEWLINE_xXMeasurable disease per RECIST 1.1 guidelines.Xx_NEWLINE_xXMeasurable disease based on RECIST 1.1Xx_NEWLINE_xXHave measurable disease per RECIST 1.1 criteriaXx_NEWLINE_xXDisease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST Version 1.1 (including skin lesions)Xx_NEWLINE_xXMeasurable disease per RECIST v1.1Xx_NEWLINE_xXSubjects with solid tumors, with the exception of CRPC, must demonstrate measurable disease, per RECIST v1.1. NOTE: Subjects with NMC that do not meet the RECIST v1.1 criteria for measurable disease, but have evaluable disease may be considered for enrollment after discussion with the GSK medical monitor..Xx_NEWLINE_xXMeasurable disease per RECIST v1.1Xx_NEWLINE_xXPatients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria version (v.) 1.1Xx_NEWLINE_xXHas measurable disease based on either modified RECIST [Nowak 2005] for thoracic disease or RECIST 1.1 elsewhereXx_NEWLINE_xXHave measurable disease (? 1 measurable lesion) based on RECIST v1.1 as determined by the site study team. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.Xx_NEWLINE_xXMeasurable disease, as defined by RECIST v1.1Xx_NEWLINE_xXHave at least 1 measurable (i.e., target) lesion per RECIST v1.1.Xx_NEWLINE_xXMeasurable disease according to RECIST 1.1 criteria.Xx_NEWLINE_xXAt least 1 target lesion that is unirradiated and measurable by RECIST, Version 1.1Xx_NEWLINE_xXMeasurable disease via RECIST v1.1 or non-measurable, evaluable disease with at least one evaluable bone lesion via RECIST v1.1Xx_NEWLINE_xXAt least one measureable lesion by RECIST 1.1.Xx_NEWLINE_xXPatients must have measurable disease as defined by RECIST 1.1.Xx_NEWLINE_xXMeasurable disease as defined by RECIST 1.1Xx_NEWLINE_xXThe subject has measurable disease or nonmeasurable, evaluable disease per RECIST 1.1. (NOTE: pleural effusions, ascites or other third fluid space are not evaluable diseases per RECIST 1.1).Xx_NEWLINE_xXPatients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria version (v.) 1.1Xx_NEWLINE_xXMeasurable disease by RECIST 1.1 criteriaXx_NEWLINE_xXMeasurable disease defined as at least one uni-dimensional measurable lesion by CT or MRI according to RECIST 1.1Xx_NEWLINE_xXMeasurable disease based on RECIST v1.1.Xx_NEWLINE_xXMeasurable disease based on RECIST v1.1.Xx_NEWLINE_xXMeasurable disease based on RECIST v1.1.Xx_NEWLINE_xXMeasurable disease as defined by modified RECIST for MPM (Byrne and Nowak, 2004)Xx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1; previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation; the pleural mesothelioma cohort will require measurable disease according to modified RECISTXx_NEWLINE_xXPrevious exposure to murine CA-125 antibody (only applicable to those patients with non-measurable disease by RECIST)Xx_NEWLINE_xXMeasurable disease according to RECIST v1.1Xx_NEWLINE_xXMeasurable disease per RECIST v1.1Xx_NEWLINE_xXPatients must have at least 1 lesion that is measurable using RECIST guidelines.Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXMeasurable disease is required for Part B expansion cohorts according to RECIST v1.1 criteria.Xx_NEWLINE_xXHave measureable disease per RECIST 1.1.Xx_NEWLINE_xXPatient must have either measurable disease by RECIST 1.1 or at least one predominantly lytic bone lesion.Xx_NEWLINE_xXSubjects must have measurable disease as defined per RECIST Version 1.1.Xx_NEWLINE_xXMeasurable disease as defined by RECIST v1.1Xx_NEWLINE_xXPresence of at least one measurable lesion according to RECIST v.1.1Xx_NEWLINE_xXDisease must be measurable by RECIST 1.1Xx_NEWLINE_xXProgressive measurable disease: using conventional solid tumour criteria RECIST 1.1.Xx_NEWLINE_xXDemonstrated progression of disease by radiological or clinical assessment (Measurable disease according to RECIST Version 1.1 is NOT required for enrollment)Xx_NEWLINE_xXMeasurable disease, according to the RECIST v1.1Xx_NEWLINE_xXSubjects must have measureable disease as defined by RECIST 1.1 criteria or modified RECIST criteriaXx_NEWLINE_xXAt least one radiographically measurable lesion per RECIST 1.1Xx_NEWLINE_xXDisease must be measurable by RECIST 1.1 criteriaXx_NEWLINE_xXNon-measurable disease according to RECIST 1.1, with the exception of bone-only non-measurable disease.Xx_NEWLINE_xXSubjects must have at least 1 measurable lesion based on RECIST version 1.1.Xx_NEWLINE_xXMeasurable disease as defined by RECIST 1.1Xx_NEWLINE_xXSubjects must have measurable disease by CT or MRI per RECIST 1.1 criteria (radiographic tumor assessment performed within 28 days of first dose of study drug) or clinically apparent disease that the investigator can follow for response per RECIST 1.1Xx_NEWLINE_xXMeasurable disease defined by RECIST version 1.1, or bone-only diseaseXx_NEWLINE_xXPatients must have at least one measurable site of disease (according to RECIST [version 1.1] criteria)Xx_NEWLINE_xXPatients must not have measurable progressive disease (RECIST 1.1)Xx_NEWLINE_xXPatients must have at least one measurable site of disease according to RECIST version 1.1 criteriaXx_NEWLINE_xXPatients with at least one measurable skin metastases and distant, measurable metastases (outside of skin) by Response Evaluation Criteria in Solid Tumors (RECIST); for patients without distant measurable metastases, an area of the skin metastases designated to not receive local therapy can be substituted; patients with multiple (>= 2) metastatic sites (skin involvement not required), with at least one site measurable by RECIST, will be eligible for the CTX/RT cohortXx_NEWLINE_xXSubjects must have at least 1 extracranial, unresectable, non-bony lesion that is measurable radiographically (based on RECIST 1.1)Xx_NEWLINE_xXMeasurable disease per RECIST v1.1 (see Appendix 3)Xx_NEWLINE_xXPresence of measurable disease per RECIST v1.1.Xx_NEWLINE_xXCancer antigen-125 (CA-125) only disease without RECIST 1.1 measurable diseaseXx_NEWLINE_xXMeasurable disease in accordance with RECIST version 1.1Xx_NEWLINE_xXDoes not have measurable disease per RECIST 1.1Xx_NEWLINE_xXPhase 1 patients must have at least two measurable tumor lesions ? 1.0 cm that are accessible to biopsy. Phase 2 patients must have at least one measurable lesion (per RECIST v1.1) which may be the same site that is used for the intratumoral injections.Xx_NEWLINE_xXMeasurable disease per RECIST 1.1 criteriaXx_NEWLINE_xXDisease must be measurable by RECIST 1.1Xx_NEWLINE_xXAt least 1 target lesion that is measurable by RECIST, Version 1.1Xx_NEWLINE_xXMeasurable disease according to RECIST 1.1.Xx_NEWLINE_xXParticipants must have measurable disease by RECIST 1.1 criteriaXx_NEWLINE_xXMeasurable disease per RECIST v1.1.Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXAt least one index lesion that will not undergo RT and which is measurable based on RECIST 1.1Xx_NEWLINE_xXPatients must have measurable disease according to the standard RECIST version 1.1; CT scans or magnetic resonance imaging (MRIs) used to assess the measurable disease must have been completed within 28 days prior to registrationXx_NEWLINE_xXMeasurable disease on CT or MRI scan by RECIST criteria (required for Phase 1b only).Xx_NEWLINE_xXEvidence of measurable disease per RECIST 1.1Xx_NEWLINE_xXParticipants must have measurable disease by RECIST v1.1 or non-measurable, evaluable disease with atleast one evaluable bone lesion by RECIST v1.1 based on radiologic scans within 28 days of Day 1 of Cycle 1Xx_NEWLINE_xXMeasurable non-CNS disease, defined by RECIST 1.1 criteriaXx_NEWLINE_xXMeasurable disease as defined by RECIST 1.1.Xx_NEWLINE_xXPatients must have measurable disease, defined by RECIST 1.1Xx_NEWLINE_xXAt least 1 target lesion that is measurable by RECIST, Version 1.1Xx_NEWLINE_xXAt least one measureable lesion as defined by RECIST version 1.1 that has not been previously irradiated.Xx_NEWLINE_xXHas measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1.Xx_NEWLINE_xXPresence of radiographically measurable disease as defined by RECIST 1.1Xx_NEWLINE_xXAt least one index lesion that will not undergo RT or ablation, and which is measurable based on RECIST 1.1Xx_NEWLINE_xXHave measurable and/or evaluable disease based on RECIST 1.1.Xx_NEWLINE_xXPatients must have one or more tumors measurable on radiographic imaging as defined by RECIST.Xx_NEWLINE_xXHave measurable disease according to RECIST v1.1 obtained by imaging within 28 days prior to registration.Xx_NEWLINE_xXMeasurable disease of at least 2 cm and otherwise based on RECIST 1.1, assessed from MRI scans by a central radiologist.Xx_NEWLINE_xXMeasurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1, and obtained by imaging within 28 days prior to registration for protocol therapy.Xx_NEWLINE_xXRadiographically measurable disease acc. to RECIST 1.1Xx_NEWLINE_xXMeasurable disease according to the RECIST criteria (version 1.1), for the evaluation of measurable diseaseXx_NEWLINE_xXPatient has measurable disease, as determined by the Investigator using RECIST, version 1.1, as determined within 28 days before baseline (C1D1).Xx_NEWLINE_xXMeasurable disease, as defined by RECIST v1.1Xx_NEWLINE_xXMeasurable disease as per RECIST v1.1Xx_NEWLINE_xXSubject must have at least 1 unidimensional measurable NSCLC lesion on a CT scan as defined by RECIST (version 1.1).Xx_NEWLINE_xXMeasurable disease based on RECIST 1.1 as determined by central reviewXx_NEWLINE_xXRadiographically-measurable disease based on RECIST 1.1Xx_NEWLINE_xXSubjects must have at least one measurable lesion per RECIST 1.1Xx_NEWLINE_xXMeasurable disease, as defined by RECIST v1.1Xx_NEWLINE_xXMeasurable disease as assessed by RECIST 1.1 criteria (Appendix A).Xx_NEWLINE_xXMeasurable disease as defined by RECIST 1.1 criteria;Xx_NEWLINE_xXMeasurable (RECIST) indicator lesion not previously irradiated.Xx_NEWLINE_xXMeasurable disease, as defined by RECIST version 1.1Xx_NEWLINE_xXMeasurable disease as assessed by modified RECIST for MPM and by RECIST 1.1 criteria for peritoneal mesothelioma, NSCLC, uveal melanoma, HCC, glioma and sarcomatoid carcinomaXx_NEWLINE_xXMeasurable or evaluable disease by RECIST 1.1Xx_NEWLINE_xXMeasurable disease, as defined by RECIST v 1.1Xx_NEWLINE_xXMeasurable or non-measurable disease is permitted as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) for phase 1b; for phase 2, patients must have measurable disease as defined in RECIST v1.1Xx_NEWLINE_xXHas at least 1 radiologically measurable lesion as defined by RECIST 1.1Xx_NEWLINE_xXMeasurable disease by RECIST 1.1 criteriaXx_NEWLINE_xXPresence of at least 1 measurable lesion according to RECIST version 1.1Xx_NEWLINE_xXPART B: Patients must have measurable disease as per RECIST version 1.1Xx_NEWLINE_xXPresence of at least one measurable lesion per RECIST 1.1 criteriaXx_NEWLINE_xXPresence of measurable lesions (RECIST V1.1)Xx_NEWLINE_xXAt least one measurable lesion as defined by modified RECIST version 1.1; previously irradiated lesions are not measurable unless the lesion is new or has demonstrated clear progression after radiationXx_NEWLINE_xXMeasurable or evaluable non-measurable disease as assessed by the investigator according to RECIST v1.1 criteriaXx_NEWLINE_xXMeasurable disease as defined by RECIST Criteria.Xx_NEWLINE_xXAt least one uni-dimensional measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to RECIST (RECIST version 1.1), and modified RECIST for HCC. Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, may be considered measurable if there has been demonstrated progression in the lesion.Xx_NEWLINE_xXEvaluable disease as determined by RECIST 1.1Xx_NEWLINE_xXMeasurable disease as defined by RECIST v1.1Xx_NEWLINE_xXMeasurable disease according to modified RECIST version 1.1Xx_NEWLINE_xXMeasurable disease according to RECIST 1.1Xx_NEWLINE_xXMust have measurable disease as defined by RECIST 1.1.Xx_NEWLINE_xXPatient has measurable disease by (RECIST).Xx_NEWLINE_xXHave evidence of measurable disease as defined by RECIST Version 1.1Xx_NEWLINE_xXMeasurable disease as defined by RECIST 1.1 criteriaXx_NEWLINE_xXMeasurable disease according to RECIST version 1.1Xx_NEWLINE_xXMeasurable disease according to RECIST v1.1Xx_NEWLINE_xXMeasurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by RECIST 1.1Xx_NEWLINE_xXMeasurable disease by RECIST version 1.1Xx_NEWLINE_xXHas measurable disease per RECIST 1.1 as determined by the local site investigator/radiology assessmentXx_NEWLINE_xXPatients must have RECIST v1.1 measurable diseaseXx_NEWLINE_xXMeasurable disease per RECIST 1.1 as determined by the investigator.Xx_NEWLINE_xXDisease must be measurable, with ?1 unidimensional measurable lesion per RECIST 1.1.Xx_NEWLINE_xXMeasurable disease by RECIST 1.1 criteriaXx_NEWLINE_xXParticipants in the Phase II portion of the trial must have measurable disease by RECIST 1.1 criteriaXx_NEWLINE_xXBreast cancer participants must have measurable disease by RECIST criteriaXx_NEWLINE_xXSubjects must have evidence of measurable disease per RECIST version 1.1 by radiographic techniques or magnetic resonance imagingXx_NEWLINE_xXFor the Extension cohorts, patients must have measurable disease by RECIST criteria and meet the following disease-specific criteria:Xx_NEWLINE_xXPatients must have measurable disease (at least one measurable lesion) as defined by RECIST criteria; all sites of disease must be evaluated within 4 weeks prior to registration to treatmentXx_NEWLINE_xXMeasurable disease as per RECIST v. 1.1.Xx_NEWLINE_xXSubject must have at least 1 measureable lesion based on RECIST V1.1. Previously irradiated lesions will not be considered as measurable lesions.Xx_NEWLINE_xXPresence of measurable disease per RECIST v1.1Xx_NEWLINE_xXMeasurable disease according to RECIST v 1.1 obtained by imaging within 28 days prior to registrationXx_NEWLINE_xXMeasurable disease by RECIST version 1.1.Xx_NEWLINE_xXMeasurable disease as per RECIST 1.1Xx_NEWLINE_xXMeasureable disease according to RECIST Version 1.1Xx_NEWLINE_xXMeasurable disease according to RECIST 1.1Xx_NEWLINE_xXMeasurable disease by CT or MRI per RECIST 1.1 criteriaXx_NEWLINE_xXMeasurable disease per RECIST v1.1 (see Appendix 6)Xx_NEWLINE_xXRadiographic progression in soft tissue or bone by modified RECIST 1.1 for subjects with measurable disease; orXx_NEWLINE_xXMeasurable disease by RECIST 1.1 criteria.Xx_NEWLINE_xXEvaluable or measurable disease, as assessed by RECIST v1.1Xx_NEWLINE_xXTumors must have measurable disease as per RECIST (version 1.1);Xx_NEWLINE_xXMeasurable disease per RECIST v1.1Xx_NEWLINE_xXAt least 1 measurable lesion as defined by RECIST v1.1Xx_NEWLINE_xXMeasurable disease by RECIST 1.1Xx_NEWLINE_xXPatients must have at least one additional lesion (measurable by RECIST v1.1 or non-target) identified as a control untreated lesion to be left untreated and followed for response.Xx_NEWLINE_xXMeasurable disease per RECIST v1.1Xx_NEWLINE_xXMeasurable disease as per RECIST v1.1Xx_NEWLINE_xXAt least one lesion measurable by RECIST not previously irradiated (Monotherapy and in Cohorts A and B)Xx_NEWLINE_xXMeasurable disease at screening by RECIST 1.1 criteriaXx_NEWLINE_xXRadiographically measurable or evaluable disease (per RECIST v1.1)Xx_NEWLINE_xXMeasurable disease per RECIST v1.1Xx_NEWLINE_xXSubjects may have measurable or non-measurable disease according to RECIST 1.1.Xx_NEWLINE_xXMeasurable disease per RECIST 1.1 guidelines. Cohort 2 may include up to 10 subjects with advanced MET amplified, G/GEJ/E adenocarcinoma with non-measurable tumor per RECIST v1.1Xx_NEWLINE_xX3. Evaluable disease, or measurable disease as assessed by RECIST version 1.1.Xx_NEWLINE_xXMeasurable disease as determined by per RECIST criteria v1.1. If the only site of measurable disease is a previously irradiated lesion, documented progression of disease and a 4 week period since radiotherapy completion is requiredXx_NEWLINE_xXAt least 1 site of disease measurable by RECIST ver1.1Xx_NEWLINE_xXAt least one measurable or non-measurable lesion as per RECIST 1.1 criteria for patients in Phase Ib; Measurable disease as determined by RECIST v1.1 for Phase II patientsXx_NEWLINE_xXMeasurable disease that can be monitored per RECIST throughout the course of study participation.Xx_NEWLINE_xXMeasurable disease according to RECIST Version 1.1 or non-measurable evaluable diseaseXx_NEWLINE_xXAt least one measurable lesion by CT scan or MRI based on RECIST version 1.1Xx_NEWLINE_xXHas measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1;Xx_NEWLINE_xXPatient must have either measurable disease by RECIST 1.1 or bone lesions in absence of measurable disease.Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXPresence of measureable disease based on RECIST v1.1Xx_NEWLINE_xXPatient must have measurable lesions as defined by RECIST version 1.1 criteriaXx_NEWLINE_xXMeasurable disease (per RECIST v1.1) prior to the start of first-line chemotherapyXx_NEWLINE_xXHave a measurable disease based on RECIST 1.1.Xx_NEWLINE_xXMeasurable disease by RECIST 1.1Xx_NEWLINE_xXMeasurable disease as per RECIST 1.1Xx_NEWLINE_xXEvaluable or measurable disease per RECIST v1.1Xx_NEWLINE_xXDisease that is measurable per RECIST v1.1Xx_NEWLINE_xXRadiologically measurable and clinically evaluable disease as per RECIST v1.1Xx_NEWLINE_xXMeasurable disease according to RECIST criteria (Version 1.1)Xx_NEWLINE_xXPatients must have measurable disease according to RECIST 1.1, and have relapsed or become refractory to conventional therapyXx_NEWLINE_xXMeasurable disease as defined by RECIST v1.1Xx_NEWLINE_xXMeaurable or evaluable extra-cranial disease as defined by RECIST v 1.1Xx_NEWLINE_xXMeasurable disease by RECIST v1.1 with at least one measurable target lesionXx_NEWLINE_xXEvaluable or measurable disease per RECIST v1.1Xx_NEWLINE_xXEvaluable or measurable disease per RECIST v1.1Xx_NEWLINE_xXMeasurable disease as defined by RECIST v1.1Xx_NEWLINE_xXMeasurable disease, as determined by radiologist evaluator, with at least 1 unidimensional measurable lesion (target lesion) by RECIST v.1.1 that has not previously been irradiated or biopsiedXx_NEWLINE_xXMeasureable disease per RECIST v1.1 prior to administration of study medicationXx_NEWLINE_xXMeasurable disease per RECIST 1.1Xx_NEWLINE_xXPatients must have measurable disease per RECIST criteria version (v.) 1.1Xx_NEWLINE_xXFor expansion: documentation by established staging studies or clinical examination to have measurable metastatic disease per RECIST v1.1 criteriaXx_NEWLINE_xXAt least one lesion measurable by RECIST Version 1.1.Xx_NEWLINE_xXMeasurable disease, as defined by RECIST v1.1; previously irradiated lesions can be counted as target lesions if clearly progressing after radiationXx_NEWLINE_xXPatients must have measurable disease defined by RECIST criteria 1.1.Xx_NEWLINE_xXMeasurable disease by RECIST v1.1 criteriaXx_NEWLINE_xXMeasurable lesion by RECIST 1.1Xx_NEWLINE_xXECOG performance status 0 or 1 5. Measurable disease per RECIST v1.1Xx_NEWLINE_xXMeasurable disease as per RECIST v1.1Xx_NEWLINE_xXMeasurable or evaluable disease by RECIST 1.1Xx_NEWLINE_xXMeasurable disease as per RECIST 1.1.Xx_NEWLINE_xXAt least one measurable lesion per RECIST v1.1. However, breast cancer patients with only bone disease are also eligible.Xx_NEWLINE_xXPatient must have measurable disease per RECIST 1.1 presented after tumour biopsy for the late disease progressionXx_NEWLINE_xXPatient has progressive and measurable disease as per RECIST 1.1. or other appropriate hematological guidelines.Xx_NEWLINE_xXPatient has progressive and measurable disease as per RECIST 1.1 or other appropriate hematological guidelines.Xx_NEWLINE_xXMeasurable disease per RECIST v1.1.Xx_NEWLINE_xXMeasurable disease per RECIST 1.1Xx_NEWLINE_xXPatients must have at least one measurable site of disease according to RECIST 1.1 that has not been previously irradiatedXx_NEWLINE_xXMeasurable disease defined as one or more target lesions according to RECISTXx_NEWLINE_xXEvaluable or measurable disease per RECIST v1.1Xx_NEWLINE_xXMeasurable disease (i.e., present with at least one measurable lesion per RECIST, version 1.1).Xx_NEWLINE_xXMeasurable tumor lesions according to RECIST 1.1 criteria.[50]Xx_NEWLINE_xXMeasurable disease by RECISTXx_NEWLINE_xXMust have measurable disease (RECIST v1.1) in at least one lesion not previously irradiated unless documented evidence of progressionXx_NEWLINE_xXAt least 1 measurable lesion per RECIST v1.1; subjects whose only measurable lesion is a lymph node will be excludedXx_NEWLINE_xXEvaluable or measurable disease per RECIST v1.1Xx_NEWLINE_xXMeasurable disease as per RECIST Version 1.1 criteria.Xx_NEWLINE_xXEvaluable or measurable disease per RECIST v1.1Xx_NEWLINE_xXAt least one measurable disease site per RECIST v1.1.Xx_NEWLINE_xXMeasurable disease as assessed by RECIST 1.1 criteria (Appendix A).Xx_NEWLINE_xXMeasurable disease defined by RECIST v1.1Xx_NEWLINE_xXHave one or more metastatic tumors measurable on CT scan or locally advanced measurable disease that has clearly progressed after prior treatment per RECIST criteria.Xx_NEWLINE_xXPatients must have presence of at least 1 lesion that is measurable or evaluable using RECIST v1.1.Xx_NEWLINE_xXDisease that is measurable per modified RECIST v1.1Xx_NEWLINE_xXMeasurable disease using RECIST criteria (version 1.1).Xx_NEWLINE_xXMeasurable radiographic evidence of disease according to RECIST v1.1Xx_NEWLINE_xXMeasurable disease per RECIST version 1.1 (Arm A and B) and modified RECIST for Arm C.Xx_NEWLINE_xXMeasurable disease (by RECIST 1.1)Xx_NEWLINE_xXMeasurable disease according to RECIST v1.1 prior to administration of study drugXx_NEWLINE_xXMeasurable disease by RECIST 1.1 with PCWG2 modificationsXx_NEWLINE_xXParticipants must have measurable disease defined as at least one target lesion that has not been irradiated and can be accurately measured in at least one dimension by RECIST v1.1 criteria.Xx_NEWLINE_xXSubject must have evaluable disease as per RECIST criteria.Xx_NEWLINE_xXMeasurable disease as defined by the RECIST v1.1.Xx_NEWLINE_xXMeasurable disease according to RECIST v1.1Xx_NEWLINE_xXMeasurable disease by RECIST 1.1 criteriaXx_NEWLINE_xXMeasurable disease as assessed by RECIST 1.1 criteria (Appendix A).Xx_NEWLINE_xXMeasurable disease on baseline imaging per RECIST 1.1 criteriaXx_NEWLINE_xXPatients must have measurable disease as defined by revised RECIST criteria (version 1.1, Appendix C) with one or more lesions that can be accurately measured in one or more dimensions within 4 weeks of entry. Areas of previous radiation may not serve as measurable disease.Xx_NEWLINE_xXThere is progression of disease documented by RECIST 1.1Xx_NEWLINE_xXRadiographically or clinically evaluable tumor. In the expansion phase, disease must be measurable according to RECIST 1.1.Xx_NEWLINE_xXMeasurable disease with at least one lesion that can be accurately measured in at least one dimension according to RECIST 1.1Xx_NEWLINE_xXMeasurable disease per RECIST v 1.1Xx_NEWLINE_xXMeasurable Disease per RECIST 1.1Xx_NEWLINE_xXMeasurable disease by RECIST v1.1Xx_NEWLINE_xXPatient must have measurable disease as defined by RECIST 1.1.Xx_NEWLINE_xXPresence of measurable disease based on RECIST v1.1.Xx_NEWLINE_xXPatients with measurable disease per RECIST 1.1 criteria\r\n* At least one lesion of >= 1.5 cm in long-axis diameter for non lymph nodes or >= 1.5 cm in short-axis diameter for lymph nodes which is serially measurable according to RECIST 1.1 using either computerized tomography (CT) or magnetic resonance imaging (MRI)\r\n* Lesions that have had radiotherapy must show evidence of progressive disease (PD) based on RECIST 1.1 to be deemed a target lesionXx_NEWLINE_xXDuring the dose expansion part of study, all patients must have at least one measurable lesion as defined by RECIST criteria.Xx_NEWLINE_xXMeasurable disease per RECIST v1.1Xx_NEWLINE_xXAt least one measurable lesion and/or non-measurable disease evaluable according to RECIST v1.1 criteriaXx_NEWLINE_xXMeasureable disease as per RECISTXx_NEWLINE_xXMeasurable disease as determined by RECIST 1.1Xx_NEWLINE_xXAt least one unidimensionally measurable lesion meeting RECIST v1.1 criteriaXx_NEWLINE_xXMeasurable disease according to RECISTXx_NEWLINE_xXMeasurable disease at baseline in accordance with RECIST Version 1.1Xx_NEWLINE_xXMeasurable or evaluable (non-measurable) disease per RECIST guidelines version 1.1.Xx_NEWLINE_xXMeasurable disease as per RECIST guideline (Version 1.1);Xx_NEWLINE_xXPart A2 & B (RCC, NSCLC, HCC, and uveal melanoma): Have measurable disease as defined by RECIST v1.1.Xx_NEWLINE_xXPatients with measurable or non-measurable disease as determined by modified RECIST version 1.0 in dose-escalation phase, and patients with at least one measurable lesion as determined by RECIST 1.0 in expansion phase.Xx_NEWLINE_xXMeasurable disease at presentation with disease measurable by RECIST required in the phase II cohortXx_NEWLINE_xXMeasurable disease according to RECIST version 1.1.Xx_NEWLINE_xXMeasurable disease according to RECIST and obtained by imaging within 30 days prior to registration for protocol therapy.Xx_NEWLINE_xXEvaluable disease or disease measurable per RECISTXx_NEWLINE_xXMeasurable disease per the RECIST criteria. For disease occurring in previously irradiated field, there must be confirmed progression prior to the date registration and more than three months after completion of radiotherapyXx_NEWLINE_xXMeasurable disease by RECIST 1.1Xx_NEWLINE_xXPatients must have measurable disease by RECIST 1.1 criteriaXx_NEWLINE_xXFor the expansion cohort only: measurable disease by RECIST v1.1 with at least one measurable target lesionXx_NEWLINE_xXAt least one measurable lesion as defined by RECIST v1.1Xx_NEWLINE_xXHave measurable disease per RECIST v.1.1.Xx_NEWLINE_xXMeasurable disease, as defined by RECIST 1.1 criteria;Xx_NEWLINE_xXEvaluable or measurable disease per RECIST, Version 1.1Xx_NEWLINE_xXSubject has measurable disease according to RECIST v1.1 criteria.Xx_NEWLINE_xXCohort A: Patients must have at least one measurable visceral lesion (per RECIST 1.1); a visceral lesion is any solid organ except for skin, lymph node, and musculoskeletal tissue; at least one of these visceral lesions must be measurable per RECIST 1.1Xx_NEWLINE_xXMeasurable disease per RECIST v1.1Xx_NEWLINE_xXSubjects must have at least one lesion that is measurable by RECIST v1.1Xx_NEWLINE_xXMeasurable disease as defined by mINRC, RANO, RECIST v1.1, or evaluable by nuclear medicine techniques, immunocytochemistry, tumor markers, or other reliable measuresXx_NEWLINE_xXMeasurable disease per RECIST 1.1 criteriaXx_NEWLINE_xXAt least 1 measurable tumor lesion per RECIST v1.1 (exception: subjects in Part 1 are not required to present with measurable disease)Xx_NEWLINE_xXAt least one tumor lesion measurable by CT or MRI scan (according to RECIST v1.1)Xx_NEWLINE_xXMeasurable disease according to RECIST v1.1 criteriaXx_NEWLINE_xXMeasurable disease at baseline as per RECIST version 1.1Xx_NEWLINE_xXMeasurable disease as defined by RECIST v1.1Xx_NEWLINE_xXMeasurable disease by RECIST criteriaXx_NEWLINE_xXEvidence of measurable disease by RECIST 1.1Xx_NEWLINE_xXMeasurable disease as defined by RECIST 1.1 within 28 days prior to registrationXx_NEWLINE_xXTumor to be irradiated as measurable by RECIST 1.1 or PRCXx_NEWLINE_xXPatient must be evaluable using RECIST 1.1 criteriaXx_NEWLINE_xXHas at least one measurable lesion per RECIST version 1.1Xx_NEWLINE_xXSubject must have measureable disease by RECIST 1.1.Xx_NEWLINE_xXMeasurable disease, defined as at least one lesion that can be accurately measured in at least one dimension by RECIST criteria version (v)1.1Xx_NEWLINE_xXMeasurable disease according to RECIST v1.1Xx_NEWLINE_xXMeasurable disease according to RECIST 1.1 criteria.Xx_NEWLINE_xXSubjects must have measurable disease by RECIST Version 1.1.Xx_NEWLINE_xXMeasurable disease by RECIST 1.1Xx_NEWLINE_xXWith the exception of patients with non-measurable neuroblastoma patients must have measurable disease as per RECIST 1.1Xx_NEWLINE_xXHas At least one measurable lesion as defined by RECIST criteriaXx_NEWLINE_xXPresence of measurable (by RECIST v1.1) and active extracranial disease will be excluded; patients with measurable extra cranial disease by RECIST v1.1 will be eligible to enroll if sites of disease are stable and not considered to be active after discussion with the sponsorXx_NEWLINE_xXPart 1, Dose Escalation: Participants may have measurable or non measurable disease as defined by RECIST 1.1/mRECIST (depending on tumor type).Xx_NEWLINE_xXEvaluable disease or disease measurable per RECIST 1.1Xx_NEWLINE_xXPatients must have currently progressive metastatic disease according to RECIST v1.1\n             criteria, ANDXx_NEWLINE_xXThe participant has measurable or non-measurable disease according to RECIST 1.0 guidelines.Xx_NEWLINE_xXPresence of measureable disease based on RECIST v1.1.Xx_NEWLINE_xXHave measurable disease based on RECIST 1.1Xx_NEWLINE_xXTo be enrolled in the dose escalation phase of the study, participants must have a radiographically or clinically evaluable tumor, but measurable disease as defined by RECIST version 1.1 [1] is not required for participation in this study.Xx_NEWLINE_xXHistologically confirmed, metastatic TNBC with measurable disease per RECIST version 1.1.Xx_NEWLINE_xXMeasurable disease per RECIST version 1.1.Xx_NEWLINE_xXMeasurable disease, as defined by RECIST v1.1Xx_NEWLINE_xXPatients must have measurable disease per RECIST v. 1.1.Xx_NEWLINE_xXPresence of measurable or non-measurable lesions as defined by irRC-RECISTXx_NEWLINE_xXDisease must be evaluable as per RECIST 1.1 or RANO (for gliomas). At least one measurable target lesion is required in expansion cohort patientsXx_NEWLINE_xXMeasurable disease as per RECIST v1.1 criteriaXx_NEWLINE_xXPresence of measureable disease based on RECIST v1.1Xx_NEWLINE_xX